Chiesi

News

Chiesi’s flagship Fabry drug heads for FDA verdict in early ...

The FDA has started its review of Israeli biotech Protalix BioTherapeutics and partner Chiesi’s Fabry disease therapy pegunigalsidase alfa, setting up a possible approval by 27

Views & Analysis

Chiesi ups its focus on rare diseases

Italy’s Chiesi has created a new business unit aimed at increasing its presence in the market for rare disease drugs.

News

Chiesi starts rare diseases division, ahead of potential Fab...

Italian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch for its Fabry Disease therapy.

News

FDA rejection scuppers AZ’s hopes of a COPD triple clash wit...

The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by

Market Access

Verona to take COPD hopeful into phase 3

Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.

News

Europe: thumbs up for Roche's Hemlibra, Chiesi rare disease ...

Drug has been approved in US since November

Chiesi’s flagship Fabry drug heads for FDA verdict in early ...

Chiesi ups its focus on rare diseases

Chiesi starts rare diseases division, ahead of potential Fab...

FDA rejection scuppers AZ’s hopes of a COPD triple clash wit...

Verona to take COPD hopeful into phase 3

Europe: thumbs up for Roche's Hemlibra, Chiesi rare disease ...

Tenax trounced by phase 3 heart failure readout

Discover a new era of healthcare panel engagement: Grounded ...

Chiesi

Editor's Picks